Superworth

RxSight profit margin RXST

Gross, operating and net profit as a share of revenue over the last twelve months, from 2021.

Net margin, 12 months
−36.8%
Operating margin, 12 months
−43.2%
Net margin on a year earlier
−14.9 pts
Peer median
6.9%

Over the twelve months to Jun 30, 2026, RxSight kept −36.8% of its revenue as net profit, with an operating margin of −43.2%.

The median for 10 medical instruments and supplies stocks of a similar size is 6.9%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY2025−29.0%−35.8%76.6%
FY2024−19.6%−26.3%70.7%
FY2023−54.6%−56.2%60.4%
FY2022n/an/a43.5%
FY2021n/an/a20.0%
FY2020n/an/a11.6%

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−36.8%−14.9 pts−43.2%
Q1 FY26−36.6%−18.7 pts−43.4%
Q4 FY25−29.0%−9.3 pts−35.8%
Q3 FY25−25.1%−1.2 pts−32.0%
Q2 FY25−21.9%+10.0 pts−28.9%
Q1 FY25−17.9%+26.1 pts−24.9%
Q4 FY24−19.6%+34.9 pts−26.3%
Q3 FY24−23.9%+47.9 pts−30.5%
Q2 FY24−31.9%+56.8 pts−36.8%
Q1 FY24−44.0%n/a−47.1%
Q4 FY23−54.6%n/a−56.2%
Q3 FY23−71.9%n/a−70.8%

Against its peers

Companies in Medical - Instruments & Supplies nearest RxSight's size, closest first, today.

CompanyProfit margin
RXSTRxSight−36.8%
PDEXPro DEX17.6%
UTMDUtah Medical Products29.0%
INFUInfuSystem6.0%
EMBCEmbecta8.6%
KEQUKewaunee Scientific3.0%
TCMDTactile Systems Technology7.1%
MDXGMimedx1.8%
MOVMovado6.0%
APTAlpha Pro Tech6.8%
IRMDIradimed26.7%
Peer median6.9%

Where RxSight ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on RxSight

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.